MWNA
KLRS

Marshall Wace North America’s Kalaris Therapeutics KLRS Stock Holding History

Marshall Wace North America’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$8.14M Hold
14,116
– – 0.03% 397
2021
Q2 		$6.41M Sell
14,116
-146
-1% -$75.4K 0.03% 481
2021
Q1 		$7.68M Buy
14,262
+146
+1% +$123K 0.03% 456
2020
Q4 		$12.5M Sell
14,116
-11,140
-44% -$8.57M 0.06% 335
2020
Q3 		$16M Buy
+25,256
New +$17.2M 0.1% 215

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIG
American International Group New York $2.93M AUM 12.08% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Marshall Wace North America's KLRS Position: Q3 2021 in Review

Marshall Wace North America held its Kalaris Therapeutics (KLRS) position steady in Q3 2021 at 14,116 shares worth $8.14M. The position accounts for 0.03% of the portfolio, ranked #397.

Marshall Wace North America first reported a position in KLRS in Q3 2020 and has held it in 5 quarters since. The position peaked at $16M in Q3 2020. 79 funds tracked by Wall St. Rank hold KLRS as of Q3 2021.

  • Marshall Wace North America held 14,116 shares of Kalaris Therapeutics worth $8.14M as of Q3 2021.
  • Marshall Wace North America left its Kalaris Therapeutics share count unchanged in Q3 2021.
  • Kalaris Therapeutics made up 0.03% of Marshall Wace North America's portfolio in Q3 2021, its #397 holding.
  • Marshall Wace North America first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 5 quarters since.
  • Marshall Wace North America's Kalaris Therapeutics position peaked at $16M in Q3 2020.
  • 79 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.